Aktie A288330 BRIDGE BIOTHERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Bridge Biotherapeutics, Inc.

Aktien

A288330

KR7288330004

A288330

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 26.06.2024 		% 5 Tage % 1. Jan.
1 852 KRW -3,49 % Intraday Chart für Bridge Biotherapeutics, Inc. -6,61 % -43,62 %
28.03. Bridge Biotherapeutics startet Forschungskooperation mit der Emory University School of Medicine zur Erforschung der Kombinationstherapie von BBT-877 bei KRAS/P53-mutierten NSCLC-Patienten, die gegen eine Anti-PD-1-Blockade resistent sind CI
26.03. Bridge Biotherapeutics kündigt Forschungskooperation mit der University of Colorado School of Medicine an, um das Potenzial von BBT-877 für die Immuno-Onkologie zu erforschen CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade
Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology
Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 1.99999872 billion in funding
Gpcr Therapeutics, Inc. Collaborates with Bridge Biotherapeutics, Inc. to Pursue Joint Development and Commercialization of the Combination Therapy
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics, Inc.(KOSDAQ:A288330) dropped from S&P Global BMI Index
Bridge Biotherapeutics to Present at the 2023 BIO International Convention
Bridge Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Bridge Biotherapeutics Inc. Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics announces preclinical study of self-discovered 4th generation lung cancer targeted therapy at AACR conference in the US
Bridge Biotherapeutics Presents Phase 2A Clinical Trial Results for BBT-401
Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022
Bridge Biotherapeutics : Material Management Information related to Judgment of Investment (US FDA approval of BBT-877 phase 2 clinical trial plan for the treatment of Idiopathic Pulmonary Fibrosis (IPF))
Bridge Biotherapeutics : Organization of Investor Relations Event
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A288330 Aktie
  4. Nachrichten Bridge Biotherapeutics, Inc.
  5. Andere Sprachen